Manejo de hemorragia pulmonar con eptacog alfa, ácido aminocaproico o ácido tranexámico en neonatos bajo cuidados intensivos.
Saved in:
| Title: | Manejo de hemorragia pulmonar con eptacog alfa, ácido aminocaproico o ácido tranexámico en neonatos bajo cuidados intensivos. |
|---|---|
| Alternate Title: | Management of pulmonary hemorrhage with eptacog alfa, aminocaproic acid or tranexamic acid in neonates receiving intensive care. |
| Authors: | Solís-Sánchez, Katy Abigail1 abigail258@hotmail.com, Miranda-Madrazo, Maria Raquel2, Rendón-Macías, Mario Enrique3, Villa-Bahena, Saúl4, Ramírez-Silva, Horacio5, Arenas, Regina Díaz-Caneja4 |
| Source: | Revista Mexicana de Pediatria. mar/abr2025, Vol. 92 Issue 2, p52-57. 6p. |
| Subjects: | TRANEXAMIC acid, HEMORRHAGE, CRITICAL care medicine, BLOOD coagulation factors, NEWBORN infants, SURVIVAL rate, AMINO acids, ANTICOAGULANTS |
| Abstract (English): | Pulmonary hemorrhage (PH) in newborns is a serious complication that can cause death. Objective: to evaluate the impact ofantihemorrhagic therapy--tranexamic acid (TA), eptacog alfa (EA), or aminocaproic acid (AA)--on newborns diagnosed with PH and treated in a Neonatal Intensive Care Unit. Material and methods: a retrospective cohort study was conducted involving 43 newborns diagnosed with PH between 2020 and 2024. All patients received one or more of the three antihemorrhagic agents, in addition to standard supportive care. Treatment outcomes were assessed based on survival, bleeding control, transfusion requirements, and recovery of hemoglobin and platelet levels. Results: of the 43 newborns included, 86% were preterm. A single antihemorrhagic agent was administered to 35 patients (TA: n = 8; EA: n = 19; AA: n = 8), while eight patients (18.6%) received a combination of two drugs. The overall survival rate was 79%, with nine deaths observed. Following initiation of antihemorrhagic therapy, transfusion requirements decreased across all cases. However, by the end of follow-up, eight patients (18.6%) remained anemic and five (11.6%) had thrombocytopenia. No differences in outcomes were observed among the three drugs used. Conclusion: antihemorrhagic therapy may offer clinical benefits in the management of PH in newborns. Nevertheless, further studies are needed to establish the efficacy and safety of these agents, particularly to clarify potential differences between EA, TA, and AA. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | La hemorragia pulmonar (HP) en recién nacidos (RN) es una complicación grave que puede causar la muerte. Objetivo: analizar el efecto del tratamiento con antihemorrágicos (ácido tranexámico [AT], eptacog alfa [EA] o ácido aminocaproico [AA]) en RN con HP, atendidos en una Unidad de Cuidados Intensivos Neonatales. Material y métodos: estudio de una cohorte retrospectiva de 43 neonatos con HP atendidos entre los años 2020 y 2024. Todos recibieron alguno de los tres fármacos (solos o en combinación), además del tratamiento convencional. El éxito del tratamiento se evaluó con la supervivencia, control del sangrado, requerimiento de hemocomponentes y en la recuperación de niveles de hemoglobina y plaquetas. Resultados: se evaluaron 43 RN, 86% pretérmino. En 35 (81%) pacientes se administró un sólo fármaco (AT: n = 8, EA: n = 19, AA: n = 8) y en ocho (18.6%) dos fármacos. Fallecieron nueve pacientes, por lo que la supervivencia fue del 79%. Posterior al inicio de los fármacos, en todos se redujo el requerimiento de transfusiones, pero al final del seguimiento ocho (18.6%) pacientes tenían anemia y cinco (11.6%) trombocitopenia. No hubo diferencia por tipo de fármaco Conclusión: al parecer, el uso de fármacos antihemorrágicos en RN con HP tiene un efecto benéfico; sin embargo, se requiere de más investigación para determinar su eficacia y seguridad, particularmente para conocer las diferencias entre EA, AT o AA. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Mexicana de Pediatria is the property of Sociedad Mexicana de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 188179729 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Manejo de hemorragia pulmonar con eptacog alfa, ácido aminocaproico o ácido tranexámico en neonatos bajo cuidados intensivos. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Management of pulmonary hemorrhage with eptacog alfa, aminocaproic acid or tranexamic acid in neonates receiving intensive care. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Solís-Sánchez%2C+Katy+Abigail%22">Solís-Sánchez, Katy Abigail</searchLink><relatesTo>1</relatesTo><i> abigail258@hotmail.com</i><br /><searchLink fieldCode="AR" term="%22Miranda-Madrazo%2C+Maria+Raquel%22">Miranda-Madrazo, Maria Raquel</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Rendón-Macías%2C+Mario+Enrique%22">Rendón-Macías, Mario Enrique</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Villa-Bahena%2C+Saúl%22">Villa-Bahena, Saúl</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Ramírez-Silva%2C+Horacio%22">Ramírez-Silva, Horacio</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Arenas%2C+Regina+Díaz-Caneja%22">Arenas, Regina Díaz-Caneja</searchLink><relatesTo>4</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Mexicana+de+Pediatria%22">Revista Mexicana de Pediatria</searchLink>. mar/abr2025, Vol. 92 Issue 2, p52-57. 6p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22TRANEXAMIC+acid%22">TRANEXAMIC acid</searchLink><br /><searchLink fieldCode="DE" term="%22HEMORRHAGE%22">HEMORRHAGE</searchLink><br /><searchLink fieldCode="DE" term="%22CRITICAL+care+medicine%22">CRITICAL care medicine</searchLink><br /><searchLink fieldCode="DE" term="%22BLOOD+coagulation+factors%22">BLOOD coagulation factors</searchLink><br /><searchLink fieldCode="DE" term="%22NEWBORN+infants%22">NEWBORN infants</searchLink><br /><searchLink fieldCode="DE" term="%22SURVIVAL+rate%22">SURVIVAL rate</searchLink><br /><searchLink fieldCode="DE" term="%22AMINO+acids%22">AMINO acids</searchLink><br /><searchLink fieldCode="DE" term="%22ANTICOAGULANTS%22">ANTICOAGULANTS</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Pulmonary hemorrhage (PH) in newborns is a serious complication that can cause death. Objective: to evaluate the impact ofantihemorrhagic therapy--tranexamic acid (TA), eptacog alfa (EA), or aminocaproic acid (AA)--on newborns diagnosed with PH and treated in a Neonatal Intensive Care Unit. Material and methods: a retrospective cohort study was conducted involving 43 newborns diagnosed with PH between 2020 and 2024. All patients received one or more of the three antihemorrhagic agents, in addition to standard supportive care. Treatment outcomes were assessed based on survival, bleeding control, transfusion requirements, and recovery of hemoglobin and platelet levels. Results: of the 43 newborns included, 86% were preterm. A single antihemorrhagic agent was administered to 35 patients (TA: n = 8; EA: n = 19; AA: n = 8), while eight patients (18.6%) received a combination of two drugs. The overall survival rate was 79%, with nine deaths observed. Following initiation of antihemorrhagic therapy, transfusion requirements decreased across all cases. However, by the end of follow-up, eight patients (18.6%) remained anemic and five (11.6%) had thrombocytopenia. No differences in outcomes were observed among the three drugs used. Conclusion: antihemorrhagic therapy may offer clinical benefits in the management of PH in newborns. Nevertheless, further studies are needed to establish the efficacy and safety of these agents, particularly to clarify potential differences between EA, TA, and AA. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: La hemorragia pulmonar (HP) en recién nacidos (RN) es una complicación grave que puede causar la muerte. Objetivo: analizar el efecto del tratamiento con antihemorrágicos (ácido tranexámico [AT], eptacog alfa [EA] o ácido aminocaproico [AA]) en RN con HP, atendidos en una Unidad de Cuidados Intensivos Neonatales. Material y métodos: estudio de una cohorte retrospectiva de 43 neonatos con HP atendidos entre los años 2020 y 2024. Todos recibieron alguno de los tres fármacos (solos o en combinación), además del tratamiento convencional. El éxito del tratamiento se evaluó con la supervivencia, control del sangrado, requerimiento de hemocomponentes y en la recuperación de niveles de hemoglobina y plaquetas. Resultados: se evaluaron 43 RN, 86% pretérmino. En 35 (81%) pacientes se administró un sólo fármaco (AT: n = 8, EA: n = 19, AA: n = 8) y en ocho (18.6%) dos fármacos. Fallecieron nueve pacientes, por lo que la supervivencia fue del 79%. Posterior al inicio de los fármacos, en todos se redujo el requerimiento de transfusiones, pero al final del seguimiento ocho (18.6%) pacientes tenían anemia y cinco (11.6%) trombocitopenia. No hubo diferencia por tipo de fármaco Conclusión: al parecer, el uso de fármacos antihemorrágicos en RN con HP tiene un efecto benéfico; sin embargo, se requiere de más investigación para determinar su eficacia y seguridad, particularmente para conocer las diferencias entre EA, AT o AA. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Mexicana de Pediatria is the property of Sociedad Mexicana de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=188179729 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.35366/121149 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 6 StartPage: 52 Subjects: – SubjectFull: TRANEXAMIC acid Type: general – SubjectFull: HEMORRHAGE Type: general – SubjectFull: CRITICAL care medicine Type: general – SubjectFull: BLOOD coagulation factors Type: general – SubjectFull: NEWBORN infants Type: general – SubjectFull: SURVIVAL rate Type: general – SubjectFull: AMINO acids Type: general – SubjectFull: ANTICOAGULANTS Type: general Titles: – TitleFull: Manejo de hemorragia pulmonar con eptacog alfa, ácido aminocaproico o ácido tranexámico en neonatos bajo cuidados intensivos. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Solís-Sánchez, Katy Abigail – PersonEntity: Name: NameFull: Miranda-Madrazo, Maria Raquel – PersonEntity: Name: NameFull: Rendón-Macías, Mario Enrique – PersonEntity: Name: NameFull: Villa-Bahena, Saúl – PersonEntity: Name: NameFull: Ramírez-Silva, Horacio – PersonEntity: Name: NameFull: Arenas, Regina Díaz-Caneja IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: mar/abr2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 00350052 Numbering: – Type: volume Value: 92 – Type: issue Value: 2 Titles: – TitleFull: Revista Mexicana de Pediatria Type: main |
| ResultId | 1 |
